Lilly’s Q4 2025 Earnings: Mounjaro and Zepbound Drive Revenue, 2026 Guidance Signals GLP-1 Momentum

Overview: A quarter powered by GLP-1 demand

Lilly (NYSE: LLY) reported its fourth-quarter 2025 financial results on February 4, 2026, highlighting a robust surge in revenue driven by its obesity medicines Mounjaro (tirzepatide) and Zepbound (semaglutide). Total revenue for Q4 2025 rose 43% to $19.3 billion, reflecting continued volume growth and new indications. Management framed the performance as evidence of durable demand for Lilly’s GLP-1 portfolio, a theme that is unlikely to fade in the near term.

On the bottom line, EPS rose meaningfully. Reported Q4 2025 EPS was $7.39, up 51% year over year, while non-GAAP EPS rose 42% to $7.54. Both metrics include a $0.52 per share charge related to acquired IPR&D, which provides a cleaner view of ongoing profitability but adds a reminder that the company’s statutory numbers carry one-time items.

Key numbers at a glance

• Revenue (Q4 2025): $19.3B (+43%)
• Reported EPS (Q4 2025): $7.39 (+51%)
• Non-GAAP EPS (Q4 2025): $7.54 (+42%)
• IPR&D charges: $0.52 per share included in the above
• 2026 revenue forecast: $80B–$83B
• 2026 non-GAAP EPS: $33.50–$35.00

Guidance for 2026: A big bet with a big number

Looking ahead, Lilly issued a 2026 revenue forecast in a broad range of $80 billion to $83 billion, paired with a non-GAAP EPS outlook of $33.50 to $35.00. The implied strategy is to monetize a broader GLP-1 and obesity medicine portfolio while continuing to scale manufacturing and access programs. The numbers are eye-catching, but they also place a ceiling on expectations if competition intensifies or if payer dynamics tighten.

Product and pipeline: Regulatory wins and pipeline momentum

The company highlighted several regulatory and pipeline milestones that undergird the 2026 outlook. Notably, the FDA approved Kwikpen for tirzepatide, supporting ease of use and patient adherence for Mounjaro. There was also an expanded indication for Jaypirca, signaling regulatory progress beyond obesity medicines and hinting at a broader oncology strategy.

In terms of the pipeline, Lilly pointed to positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, as well as for forglipron (an oral incretin) for obesity and potential expansion into type 2 diabetes in the EU. Retatrutide, another obesity-focused program, was cited as part of the obesity/knee osteoarthritis narrative. Taken together, the updates reinforce the thesis that Lilly aims to diversify growth beyond Mounjaro and Zepbound while leveraging a vertically integrated platform.

Regulatory progress and market dynamics

Management underscored a U.S. government agreement to expand access to obesity medicines, a development that could translate into broad volume gains but also raises questions about pricing, affordability, and long-term payer risk. Such dynamics will be watched closely by EPS consensus expectations across the sector, as investors weigh whether Lilly’s volume upside justifies premium pricing narratives in a high-growth category.

What this means for Lilly and its peers

The Q4 strength and the 2026 guidance place Lilly at the center of the GLP-1 debate—the class and its monetization strategies. The company’s narrative hinges on sustaining adoption of Mounjaro and Zepbound while expanding into oral formats and new indications. For sector peers, the message is twofold: first, the market for obesity and metabolic medicines remains large and underpenetrated; second, execution—regulatory timing, access programs, and manufacturing capacity—will determine whether rivals can close the gap on Lilly’s running start.

Investors should watch how the revenue forecast and EPS progression align with ongoing R&D investments and potential pricing pressures. The strength of the obesity franchise may attract more competition, but Lilly’s breadth of approvals and pipeline momentum could keep it ahead in the near to medium term.

Risks and interpretation

Key questions include: Will payer coverage expand uniformly across geographies, or will there be regional divergence that weighs on sequential growth? How will pricing and discounts evolve as the obesity medicines franchise scales? And how durable is the lift from the FDA’s and other regulators’ approvals as Lilly pivots to oral formulations and new indications?

For earnings surprise watchers, the reported results imply a solid management cadence, but the absence of explicit EPS consensus figures in the release means outsiders must rely on company-provided ranges and market chatter to gauge near-term consensus shifts. Still, the magnitude of the Q4 beat and the 2026 guidance suggests the street would be inclined to treat Lilly as a core beneficiary of GLP-1-driven growth—so long as the underlying demand remains intact and competition remains manageable.

Conclusion: A runway carved by demand and discipline

Lilly’s Q4 2025 results reinforce a narrative of persistent demand for advanced obesity therapies and a strategy to convert that demand into durable revenue and earnings growth. The company’s 2026 revenue forecast and EPS range imply substantial progress but also a commitment to disciplined execution amid a competitive and regulatory-rich environment. If the obesity market sustains its momentum, Lilly’s trajectory could influence peers to push for broader indications, faster read-through to earnings per share, and more ambitious revenue forecast targets—while keeping a wary eye on the economics of access programs and reimbursement dynamics.

As Lilly strides into 2026, the market will be listening not just for raw numbers but for consistency: the tempo of approvals, the cadence of launches, and the degree to which >=$80 billion in revenue becomes a believable floor rather than a ceiling. In the grand ledger of pharma growth stories, this one looks like a patient undertaking with a few hundred million doses of optimism sprinkled in—enough to keep the chartists smiling and the skeptics on the edge of their seats.